Article info
PDFReviews
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- Correspondence to Dr David Hunt, Clinical Lecturer in Neurology, Department of Clinical Neurosciences, University of Edinburgh, Chancellor's Building, Little France, Edinburgh, Midlothian, EH16 4SB, UK; david.hunt{at}luht.scot.nhs.uk
Citation
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
Publication history
- Received August 2, 2011
- Accepted December 8, 2011
- First published January 18, 2012.
Online issue publication
March 29, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy
- Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies
- Lessons for clinical trials from natalizumab in multiple sclerosis
- Natalizumab and progressive multifocal leucoencephalopathy
- No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study
- Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy
- Cerebellar progressive multifocal leucoencephalopathy identified by the shrimp sign
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy